Texas 89th Legislature, Regular Session Status: Introduced

HB 3785 — Relating to labeling requirements for compounded drug products.

Last action — Failed to receive affirmative vote in comm.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 89th Legislature, Regular Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Relating to labeling requirements for compounded drug products.

Bill Text

We don't have the full text on file for this bill yet.

Read HB 3785 on the official Texas source →

How this bill changes current law

1 change Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

This bill amends 1 section(s) of the Texas statutes: Section 562.157, Occupations Code.

  • Section 562.157, Occupations Code

    Sec. 562.157. LABELING OF COMPOUNDED DRUG PRODUCTS. (a) This section applies to: (1) a pharmacy that compounds a sterile or non-sterile preparation; and (2) a manufacturer or other entity that compounds a drug intended to be distributed: (A) through a telepharmacy service; (B) by over-the-counter sale; or (C) directly from a pharmacist to a patient. (b) A pharmacist may not furnish or dispense a compounded drug to a patient unless the drug is labeled with the following information: (1) the patient's name; (2) the name, address, telephone number, and license number of: (A) the pharmacy furnishing or dispensing the compounded drug; or (B) the pharmacy that prepared the compounded drug, if that is not the same pharmacy described by Paragraph (A); (3) the statement "Compounded Drug, Substitute for (insert name of drug applicable to the compound)"; (4) all active ingredients used to prepare the compounded drug; (5) the compounded drug's beyond-use date, as determined by the pharmacist using appropriate documented criteria; (6) the quantity or amount of the compounded drug in the container dispensed to the patient; (7) appropriate ancillary instructions, including: (A) storage instructions; and (B) cautionary instructions or statements, including any hazardous drug warning; (8) directions for use, including all appropriate: (A) dosage directions; and (B) other administration directions, including as applicable, the appropriate dosage level per time interval; (9) any side effects noted from trials, research, and other appropriate information sources; (10) whether the compounded drug was prepared in a sterile facility or a non-sterile facility; and (11) whether the compounded drug was prepared in a location outside of the pharmacy that furnishes the drug to the patient. (c) The board shall adopt rules regarding the labeling requirements of Subsection (b) in accordance with other existing labeling requirements.

    added

Action History

  1. Failed to receive affirmative vote in comm.

  2. Committee substitute considered in committee

  3. Considered in public hearing

  4. Left pending in committee

  5. Testimony taken/registration(s) recorded in committee

  6. Considered in public hearing

  7. Scheduled for public hearing on . . .

  8. Referred to Public Health

  9. Read first time

  10. Filed

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 183 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (183)

183 members have not signed on to this bill.

Show all 183 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 3785 do?
Relating to labeling requirements for compounded drug products.
Who sponsors HB 3785?
HB 3785 is sponsored by Barbara Gervin-Hawkins.
What is the current status of HB 3785?
This bill died with 89th Legislature, Regular Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 3785?
Track HB 3785 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 3785

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 3785

Last checked for changes 4 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →